Atrial remodeling and novel pharmacological strategies for antiarrhythmic therapy in atrial fibrillation

Current Medicinal Chemistry

Volumn 18, Issue 24, 2011, Pages 3675-3694

  Jost, N ^a,c   Kohajda, Z ^c   Kristof A ^c   Kovacs P P ^a   Husti, Z ^a   Juhasz V ^a   Kiss, L ^b   Varro A ^a,c   Virag L ^a   Baczko I ^a  

^a UNIVERSITY OF SZEGED   (Hungary)

^b UNIVERSITY OF SZEGED   (Hungary)

^c INSTITUTE OF EXPERIMENTAL MEDICINE   (Hungary)

Author keywords

Antiarrhythmic drugs; Atrial fibrillation; Atrial remodeling

Indexed keywords

2 [2 [4 (4 NITROBENZYLOXY)PHENYL]ETHYL]ISOTHIOUREA METHANESULFONATE; 2 [4 (2,5 DIFLUOROBENZYLOXY)PHENOXY] 5 ETHOXYANILINE; 2' (4 METHOXYPHENYLACETAMIDOMETHYL) N [2 (3 PYRIDYL)ETHYL] 2 BIPHENYLCARBOXAMIDE; 4 AMINOPYRIDINE; ACACETIN; ANTIARRHYTHMIC AGENT; AVE 1231; AZIMILIDE; CALCIUM CHANNEL L TYPE; DANEGAPTIDE; DIPHENYLPHOSPHINE OXIDE; DOFETILIDE; DPO 1; DRONEDARONE; GAP JUNCTION PROTEIN; INAKALANT; ISQ 1; N [3 HYDROXY 2,2 DIMETHYL 6 (4,4,4 TRIFLUOROBUTOXY)CHROMAN 4 YL] N METHYLMETHANESULFONAMIDE; NIP 141; NIP 142; PLACEBO; RANOLAZINE; ROTIGAPTIDE; S 20951; S 9947; SODIUM CALCIUM EXCHANGE PROTEIN; TEDISAMIL; UNCLASSIFIED DRUG; UNINDEXED DRUG; VERNAKALANT; XEND 0101;

ACTION POTENTIAL; ANTIARRHYTHMIC ACTIVITY; APOPTOSIS; ARTICLE; CALCIUM CURRENT; CLINICAL TRIAL; CORONARY ARTERY DISEASE; DISEASE ASSOCIATION; DISEASE PREDISPOSITION; GAP JUNCTION; HEART ARRHYTHMIA; HEART ATRIUM; HEART ATRIUM FIBRILLATION; HEART CONDUCTION; HEART CONTRACTION; HEART FAILURE; HEART FUNCTION; HEART MUSCLE; HEART MUSCLE CELL; HEART MUSCLE POTENTIAL; HEART STIMULATION; HEART SUPRAVENTRICULAR ARRHYTHMIA; HEART VENTRICLE EXTRASYSTOLE; HEART VENTRICLE TACHYCARDIA; HISTOPATHOLOGY; HUMAN; LONG QT SYNDROME; MEMBRANE STEADY POTENTIAL; MORBIDITY; MORTALITY; NONHUMAN; PACEMAKER; PATHOPHYSIOLOGY; PREVALENCE; PROTEIN EXPRESSION; REENTRY ARRHYTHMIA; SUPRAVENTRICULAR TACHYCARDIA; SYNAPSE; TACHYCARDIA;

ANTI-ARRHYTHMIA AGENTS; ATRIAL FIBRILLATION; ATRIAL FUNCTION; HEART ATRIA; HUMANS; ION CHANNELS;

EID: 80051967483     PISSN: 09298673     EISSN: 1875533X     Source Type: Journal    
DOI: 10.2174/092986711796642373     Document Type: Article

References (198)

1. Go AS, Hylek EM, Phillips KA, Chang Y, Henault LE, Selby J V, Singer DE. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. JAMA. 2001; 285:2370-2375. (Pubitemid 32424106)
2. Miyasaka Y, Barnes ME, Gersh BJ, Cha SS, Bailey KR, Abhayaratna WP, Seward JB, Tsang TS. Secular trends in incidence of atrial fibrillation in Olmsted County, Minnesota, 1980 to 2000, and implications on the projections for future prevalence. Circulation, 2006; 114:119-125. (Pubitemid 44420743)
3. Prior D, Coller J. Echocardiography in heart failure - A guide for general practice. Aust Fam Physician., 2010; 39:904-909.
4. Schotten U, Duytschaever M, Ausma J, et al. Electrical and contractile remodeling during the first days of atrial fibrillation go hand in hand. Circulation, 2003; 107:1433-1439. (Pubitemid 36350744)
5. Sellers MB, Newby LK Atrial fibrillation, anticoagulation, fall risk, and outcomes in elderly patients. Am Heart J., 2011; 161:241-246.
6. Katritsis DG, Toumpoulis IK, Giazitzoglou E, Korovesis S, Karabinos I, Paxinos G, Zambartas C, Anagnostopoulos CE Latent arterial hypertension in apparently lone atrial fibrillation. J Interv Card Electrophysiol., 2005; 13:203-207. (Pubitemid 41367257)
7. Karthikeyan G, Eikelboom JW. The CHADS2 score for stroke risk stratification in atrial fibrillation - friend or foe? Thromb Haemost, 2010; 104:45-48.
8. Kopecky SL, Gersh BJ, McGoon MD, et al The natural history of lone atrial fibrillation. A population-based study over three decades. N Engl J Med, 1987; 317:669-674. (Pubitemid 17138192)
9. Rizos T, Rasch C, Jenetzky E, Hametner C, Kathoefer S, Reinhardt R, Hepp T, Hacke W, Veltkamp R. Detection of paroxysmal atrial fibrillation in acute stroke patients. Cerebrovasc Dis., 2010; 30:410-417.
10. Hindricks G, Pokushalov E, Urban L, Taborsky M, Kuck KH, Lebedev D, Rieger G, Pürerfellner H; XPECT Trial Investigators. Performance of a new leadless implantable cardiac monitor in detecting and quantifying atrial fibrillation: Results of the XPECT trial. Circ Arrhythm Electrophysiol, 2010; 3:141-147.
11. Kosior DA, Szulc M, Opolski G, Torbicki A, Rabczenko D. Long-term sinus rhythm maintenance after cardioversion of persistent atrial fibrillation: is the treatment's success predictable? Heart Vessels., 2006; 21:375-381.
12. Wijffels MCEF, Kirchhof CJHJ, Dorland R, et al Atrial fibrillation begets atrial fibrillation. A study in awake, chronically instrumented conscious goats. Circulation, 1995; 92:1954-1968.
13. Allessie M, Ausma J, Schotten U: Electrical, contractile and structural remodeling during atrial fibrillation. Cardiovasc Res, 2002; 54:230-246. (Pubitemid 34327903)
14. Nattel S: Atrial electrophysiological remodeling caused by rapid atrial activation: underlying mechanisms and clinical relevance to atrial fibrillation. Cardiovasc Res, 1999; 42:298-308. (Pubitemid 29243158)
15. Lloyd MS, Langberg J: Recurrences of atrial fibrillation after ablation: when will this hydra meet its Hercules? J Cardiovasc Electrophysiol 2006; 17: 236-237. (Pubitemid 43344928)
16. Nattel S, Burstein B, Dobrev D. Atrial remodeling and atrial fibrillation: mechanisms and implications. Circ Arrhythm Electrophysiol., 2008; 1:62-73.
17. Vincenti A, Brambilla R, Fumagalli MG, Merola R, Pedretti S. Onset mechanism of paroxysmal atrial fibrillation detected by ambulatory Holter monitoring. Europace., 2006; 8:204-210. (Pubitemid 43905752)
18. Allessie, M. A., Bonke, F. I., & Schopman, F. J. (1977). Circus movement in rabbit atrial muscle as a mechanism of tachycardia. III. The "Leading Circle" concept: a new model of circus movement in cardiac tissue without the involvement of an anatomical obstacle. Circ Res, 41, 9-18. (Pubitemid 8132078)
19. Zipes DP, Knope RF: Electrical properties of the thoracic veins. Am J Cardiol 1972; 29: 372-376.
20. Mansour M, Ruskin J, Keane D. Initiation of atrial fibrillation by ectopic beats originating from the ostium of the inferior vena cava. J Cardiovasc Electrophysiol., 2002; 13:1292-1295. (Pubitemid 36042730)
21. Berenfeld O, Zaitsev AV, Mironov SF, et al Frequency dependent breakdown of wave propagation into fibrillatory conduction across the pectinate muscle network in the isolated sheep right atrium. Circ Res, 2002; 90:1173-1180. (Pubitemid 34786902)
22. Moe GK, Abildskov JA. Atrial fibrillation as a self-sustaining arrhythmia independent of focal discharge. Am Heart J., 1959; 58:59-70.
23. Rensma PL, Allessie MA, Lammers WJ, et al Length of excitation wave and susceptibility to reentrant atrial arrhythmias in normal conscious dogs. Circ Res, 1988; 62:395-410. (Pubitemid 18041961)
24. Lammers WJ, Allessie MA: Pathophysiology of atrial fibrillation: current aspects. Herz, 1993; 18:1-8. (Pubitemid 23076179)
25. Fazekas T, Scherlag BJ, Mabo P, et al Facilitation of reentry by lidocaine in canine myocardial infaction. Am Heart J 1994; 127: 345-352. (Pubitemid 24063226)
26. Nattel S, Maguy A, Le Bouter S, et al Arrhythmogenic ion-channel remodeling in the heart: heart failure, myocardial infarction, and atrial fibrillation. Physiol Rev, 2007; 87:425-456. (Pubitemid 47084677)
27. Cha TJ, Ehrlich JR, Chartier D, et al Kir3-based inward rectifier potassium current: potential role in atrial tachycardia remodeling effects on atrial repolarization and arrhythmias. Circulation, 2006; 113:1730-1737. (Pubitemid 43958465)
28. Olsson SB, Cotoi S, Varnauskas E: Monophasic action potentials and sinus rhythm stability after conversion of atrial fibrillation. Acta Med Scand, 1971; 190: 381-387.
29. Attuel P, Childers R, Cauchemez B, et al Failure in the rate adaptation of the atrial refractory period: its relationship to vulnerability. Int J Cardiol., 1982; 2:179-197. (Pubitemid 13238751)
30. Papp R, Gönczi M, Kovács M, et al Gap junctional uncoupling plays a trigger role in the antiarrhythmic effect of ischaemic preconditioning. Cardiovasc Res, 2007; 74:396-405. (Pubitemid 46711090)
31. van der Velden HM, Ausma J, Rook MB, et al Gap junctional remodeling in relation to stabilization of atrial fibrillation in the goat. Cardiovasc Res, 2000; 46:476-486. (Pubitemid 30319333)
32. + current in a chronic dog model of atrial fibrillation. Circ Res 1997; 81:1045-1052. (Pubitemid 27514955)
33. Shi Y, Ducharme A, Li D, et al Remodeling of atrial dimensions and emptying function in canine models of atrial fibrillation. Cardiovasc Res 2001; 52:217-225. (Pubitemid 33000398)
34. Henry WL, Morganroth J, Pearlman AS, et al Relation between echocardio-graphically determined left atrial size and atrial fibrillation. Circulation, 1976; 53:273-279.
35. f) channel mRNA in human atrial tissue: correlation with left atrial filling pressure and atrial fibrillation. J Cardiovasc Electrophysiol, 1999; 10:947-953.
36. Janse MJ, Wilde AA. Molecular mechanisms of arrhythmias. Rev Port Cardiol., 1998; 17 Suppl 2:II41-46.
37. Chia BL. Digitalis-induced cardiac arrhythmias. Angiology., 1981; 32:630-638. (Pubitemid 11002132)
38. Stambler BS, Fenelon G, Shepard RK, et al. Characterization of sustained atrial tachycardia in dogs with rapid ventricular pacing-induced heart failure. J Cardiovasc Electrophysiol, 2003; 14:499-507. (Pubitemid 36583911)
39. Yeh YH, Wakili R, Qi X et al. Calcium handling abnormalities underlying atrial arrhythmogenesis and contractile dysfunction in dogs with congestive heart failure. Circ Arrhythmia Electrophysiol 2008; 1:93-102.
40. Nattel S, Quantz MA: Pharmacological response of quinidine induced early afterdepolarisations in canine cardiac Purkinje fibres: insights into underlying ionic mechanisms. Cardiovasc Res, 1988; 22:808-817. (Pubitemid 18268710)
41. Burashnikov A, Shimizu W, Antzelevitch C. Fever accentuates transmural dispersion of repolarization and facilitates development of early afterdepo-larizations and torsade de pointes under long-QT Conditions. Circ Arrhythm Electrophysiol., 2008; 1:202-208.
42. Satoh T, Zipes DP: Cesium-induced atrial tachycardia degenerating into atrial fibrillation in dogs: atrial torsades de pointes? J Cardiovasc Electrophysiol, 1998; 9: 970-984.
43. Burashnikov A, Antzelevitch C: Reinduction of atrial fibrillation immediately after termination of the arrhythmia is mediated by late phase 3 early afterdepolarization-induced triggered activity. Circulation, 2003; 107:2355-2360. (Pubitemid 36578508)
44. Kirchhof P, Eckardt L, Franz MR, et al. Prolonged atrial action potential durations and polymorphic atrial tachyarrhythmias in patients with long QT syndrome. J Cardiovasc Electrophysiol, 2003; 14: 1027-1033. (Pubitemid 37412078)
45. Chen YJ, Chen SA, Chen YC, et al. Effects of rapid atrial pacing on the arrhythmogenic activity of single cardiomyocytes from pulmonary veins: implication in initiation of atrial fibrillation. Circulation, 2001; 104:2849 - 2854.
46. 2+ release causes myocyte depolarization. Underlying mechanism and threshold for triggered action potentials. Circ Res, 2000; 87: 774-780.
47. Franz MR: Atrial fibrillation and atrial flutter seen through the "eye" of monophasic action potential recordings. In Atrial flutter and fibrillation. From basic to clinical apllications. Saoudi N, Schoels W, El-Sherif N (eds), Futura Publishing Co., Inc, Armonk, New York, 1998, p. 177-191.
48. Narayan SM, Bode F, Karasik PL, et al. Alternans of atrial action potentials during atrial flutter as a precursor to atrial fibrillation. Circulation, 2002; 106: 1968-1973. (Pubitemid 35176303)
49. Narayan SM, Krummen DE, Kahn AM, et al. Evaluating fluctuations in human atrial fibrillatory cycle length using monophasic action potentials. Pacing Clin Electrophysiol, 2006; 29:1209-1218. (Pubitemid 44707102)
50. K,ACh and muscarinic receptor-mediated shortening of action potentials. Circulation, 2001; 104: 2551-2557. (Pubitemid 33104792)
51. Yue L, Feng J, Gaspo R, et al. Ionic remodeling underlying action potential changes in a canine model of atrial fibrillation. Circ Res, 1997; 81:512-525. (Pubitemid 27432738)
52. 2+ current density in chronic human atrial fibrillation is associated with increased activity of protein phosphatases. Circulation, 2004; 110: 2651-2657. (Pubitemid 39453015)
53. K,ACh is constitutively active in patients with chronic atrial fibrillation. Circulation, 112: 3697 - 3706, 2005. (Pubitemid 43739509)
54. Sun H, Gaspo R, Leblanc N, et al. Cellular mechanisms of atrial contractile dysfunction caused by sustained atrial tachycardia. Circulation, 1998; 98:719-727. (Pubitemid 28387499)
55. Cheng H, Lederer WJ Calcium sparks. Physiol Rev., 2008; 88:1491-1545.
56. Bosch RF, Zeng X, Grammer JB, et al. Ionic mechanisms of electrical remodeling in human atrial fibrillation. Cardiovasc Res, 1999; 44: 121-131. (Pubitemid 29431690)
57. Brundel BJJM, Van Gelder IC, Henning RH, et al. Ion channel remodeling is related to intraoperative atrial effective refractory periods in patients with paroxysmal and persistent atrial fibrillation. Circulation, 2001; 103: 684-690. (Pubitemid 32144197)
58. Yue L, Melnyk P, Gaspo R, et al. Molecular mechanisms underlying ionic remodeling in a dog model of atrial fibrillation. Circ Res, 1999; 84: 776 - 784. (Pubitemid 29181484)
59. Gaborit N, Steenman M, Lamirault G, et al. Human atrial ion channel and transporter subunit geneexpression remodeling associated with valvular heart disease and atrial fibrillation. Circulation, 2005; 112: 471-481. (Pubitemid 41060786)
60. Amin AS, Tan HL, Wilde AA: Cardiac ion channels in health and disease. Heart Rhythm. 2010; 7:117-126.
61. 2+ currents and human atrial fibrillation. Circ Res 1999; 85:428-426.
62. Skasa M, Jüngling E, Picht E, et al. L-type calcium currents in atrial myocytes from patients with persistent and non-persistent atrial fibrillation. Basic Res Cardiol, 2001; 96: 151-159. (Pubitemid 32236784)
63. Brundel BJ, Van Gelder IC, Henning RH, et al. Gene expression of proteins influencing the calcium homeostasis in patients with persistent and paroxysmal atrial fibrillation. Cardiovasc Res, 1999; 42: 443-454. (Pubitemid 29243170)
64. 2+-ATPase mRNA in human atrial fibrillation without significant change in the mRNA of ryanodine receptor, calsequestrin and phospholamban. J Am Coll Cardiol, 1999; 33: 1231-1237.
65. Gonzalez DR, Treuer A, Sun QA, Stamler JS, Hare JM. S-Nitrosylation of cardiac ion channels. J. Cardiovasc Pharmacol. 2009 54:188-195.
66. 2+ channel subunits alpha1C and beta2 are not downregulated in atrial myocardium of patients with chronic atrial fibrillation. J Mol Cell Cardiol, 2003; 35:437-443. (Pubitemid 36539450)
67. to in rapid atrial pacing in rabbits. J Am Coll Cardiol, 2003; 41:858-869. (Pubitemid 36308398)
68. Blaustein MP & Lederer WJ. Sodium/calcium exchange: ist physiological implications. Physiol Rev 1999; 79:763-854. (Pubitemid 29330173)
69. 2+ exchange. Molecular and pharmacological aspects. Circ Res, 2001; 88: 864-876. (Pubitemid 32441464)
70. Schotten U, Greiser M, Benke D, et al. Atrial fibrillation induced atrial contractile dysfunction: a tachycardiomyopathy of a different sort. Cardiovasc Res, 2002; 53: 192-201. (Pubitemid 34020780)
71. Yeh YH, Burstein B, Qi X Y, et al. Funny current downregulation and sinus node dysfunction associated with atrial tachyarrhythmia: a molecular basis for tachycardia-bradycardia syndrome. Circulation. 2009; 119:1576-1785.
72. Hara M, Shvilkin A, Rosen MR, et al. Steady-state and nonsteady-state action potentials in fibrillating canine atrium: abnormal rate adaptation and its possible mechanisms. Cardiovasc Res, 1999; 42: 455-469. (Pubitemid 29243171)
73. Anumonwo JM, Lopatin AN: Cardiac strong inward rectifier potassium channels. J Mol Cell Cardiol, 2010; 48: 45-54.
74. K1 up-regulation in human atrial fibrillation. Heart Rhythm 2009; 6:1802-1809.
75. Heidbüchel H, Vereecke J, Carmeliet E: Three different potassium channels in human atrium: contribution to the basal potassium conductance. Circ Res 1990; 66: 1277-1286. (Pubitemid 20147744)
76. Breitwieser GE, Szabo G. Uncoupling of cardiac muscarinic and betaadrenergic receptors from ion channels by a guanine nucleotide analogue. Nature, 1985; 317:538-540. (Pubitemid 16224161)
77. Yamada M, Inanobe A, Kurachi Y: G protein regulation of potassium ion channels. Pharmacol Rev, 1998; 50: 723-757. (Pubitemid 29028816)
78. Liu L, Nattel S.: Differing sympathetic and vagal effects on atrial fibrillation in dogs: role of refractoriness heterogeneity. Am J Physiol 1997; 273: H805- H816.
79. Coumel P, Attuel P, Lavallée J, et al. Syndrome d'arythmie auriculaire d'origine vagale. Arch Mal Coeur 1978; 6: 643-656.
80. Yeh Y-H, Lemola K, Nattel S: Vagal atrial fibrillation. Acta Cardiol Sin, 2007; 23:1-12. (Pubitemid 46770055)
81. K,ACh channels in patients with chronic atrial fibrillation. Cardiovasc Res, 2007; 74: 426-437. (Pubitemid 46693702)
82. K,ACh single channel activity with atrial tachycardia remodeling in canine atrial cardiomyocytes. Cardiovasc Res 2008; 77: 35-43. (Pubitemid 351195163)
83. KACh blocker, terminates atrial fibrillation with selective atrial effective refractory period prolongation. Pharmacol Res, 2006; 54: 136-141. (Pubitemid 44038385)
84. Kr-blocker dofetilide. J Cardiovasc Pharmacol, 2008; 51: 162-169. (Pubitemid 351301477)
85. Noma A. ATP-regulated K+ channels in cardiac muscle, Nature, 1983; 305:147-149.
86. K,ATP current density and allosteric modulation during chronic atrial fibrillation. Chin Med J 2005; 118: 1161-1166. (Pubitemid 41051615)
87. +) current density during chronic human atrial fibrillation. J Mol Cell Cardiol., 2003; 35:1399-1405. (Pubitemid 37491183)
88. + channels. J Am Coll Cardiol, 2001;37:926-932. (Pubitemid 32202465)
89. Flagg T P, Kurata HT, Masia R, Caputa G, Magnuson MA, Lefer DJ, Coetzee WA, Nichols CG. Differential structure of atrial and ventricular KATP: atrial KATP channels require SUR1. Circ Res, 2008; 103:1458-1465.
90. Litovsky SH, Antzelevitch C. Transient outward current prominent in canine ventricular epicardium but not endocardium. Circ Res, 1988; 62:116-126. (Pubitemid 18032082)
91. Wettwer E, Amos GJ, Posival H, Ravens U. Transient outward current in human ventricular myocytes of subepicardial and subendocardial origin. Circ Res, 1994; 75:473-482. (Pubitemid 24256408)
92. + current densities and Kv1.5 expression are reduced in chronic human atrial fibrillation. Circ Res, 1997; 80: 772-781. (Pubitemid 27230051)
93. Workman AJ, Kane KA, Rankin AC: The contribution of ionic currents to changes in refractoriness of human atrial myocytes associated with chronic atrial fibrillation. Cardiovasc Res, 2001; 52: 226-235. (Pubitemid 33000399)
94. Caballero R, de la Fuente MG, Gómez R, et al. In humans, chronic atrial fibrillation decreases the transient outward current and ultrarapid component of the delayed rectifier current differentially on each atria and increases the slow component of the delayed rectifier current in both. J Am Coll Cardiol, 2010; 55: 2346-2354.
95. Grammer JB, Bosch RF, Kühlkamp V, et al. Molecular remodeling of Kv4.3 potassium channels in human atrial fibrillation. J Cardiovasc Electrophysiol, 2000; 11: 626-633. (Pubitemid 30397533)
96. + current in human atrial fibrillation. Their possible role in postoperative atrial fibrillation. J Mol Cell Cardiol, 2000; 32: 1885-1896.
97. Kur-blocker, ISQ-1, in rat, dog, and nonhuman primate. J Cardiovasc Pharmacol, 2007; 49: 236-245. (Pubitemid 46626016)
98. Wang Z, Fermini B, Nattel S: Effects of flecainide, quinidine, and 4-aminopyridine on transient outward and ultrarapid delayed rectifier currents in human atrial myocytes. J Pharmacol Exp Ther, 1995; 272:184-196.
99. + current similar to Kv1.5 cloned channel currents. Circ Res, 1993; 73:1061-1076. (Pubitemid 23340202)
100. Kur in controlling action potential shape and contractility in the human atrium: influence of chronic atrial fibrillation. Circulation, 2004; 110: 2299-2306. (Pubitemid 39407330)
101. Courtemanche M, Ramirez RJ, Nattel S: Ionic targets for drug therapy and atrial fibrillation-induced electrical remodeling: insights from a mathematical model. Cardiovasc Res, 1999; 42:477-489. (Pubitemid 29243173)
102. Lai L P, Su MJ, Lin JL, et al. Changes in the mRNA levels of delayed rectifier potassium channels in human atrial fibrillation. Cardiology, 92: 248-255, 1999.
103. Heidbüchel H: A paradigm shift in treatment of atrial fibrillation: from electrical to structural therapy? Eur Heart J, 2003; 24: 2077-2078. (Pubitemid 37486524)
104. Burstein B, Nattel S. Atrial fibrosis: mechanisms and clinical relevance in atrial fibrillation. J Am Coll Cardiol., 2008; 51:802-809. (Pubitemid 351260071)
105. Assayag P, Carre F, Chevalier B, et al. Compensated cardiac hypertrophy: arrhythmogeneicity and the new myocardial phenotype. I. Fibrosis. Cardiovasc Res, 1997; 34: 439-444. (Pubitemid 27272662)
106. Silver MA, Pick R, Brilla CG, et al: Reactive and reparative fibrillar collagen remodeling in the hypertrophied rat left ventricle: two experimental models of myocardial fibrosis. Cardiovasc Res, 1990; 24: 741-747. (Pubitemid 20289625)
107. Gronich N, Kumar A, Zhang Y, Efimov IR, Soldatov NM. Molecular remodeling of ion channels, exchangers and pumps in atrial and ventricular myocytes in ischemic cardiomyopathy. Channels (Austin), 2010; 4:101-107.
108. Nattel S, Opie LH: Controversies in atrial fibrillation. Lancet, 2006; 367: 262-272. (Pubitemid 43107672)
109. Frustaci A, Chimenti C, Bellocci F, et al. Histological substrate of atrial biopsies in patients with lone atrial fibrillation. Circulation, 1997; 96: 1180-1184. (Pubitemid 27344221)
110. Schnabel RB, Larson MG, Yamamoto JF, et al. Relations of biomarkers of distinct patophysiological pathways and atrial fibrillation incidence in the community. Circulation, 2010; 121: 200-207.
111. Toutouzas K, Synetos A, Drakopoulou M, et al. The role of inflammation in atrial fibrillation: a myth or a fact? Am J Med Sci, 2009; 338: 494-499.
112. Nakazawa Y, Ashihara T, Tsutamoto T, et al. Endothelin-1 as a predictor of atrial fibrillation recurrence after pulmonary vein isolation. Heart Rhythm, 2009; 6:725-730.
113. Li J, Solus J, Chen Q, et al: Role of inflammation and oxidative stress in atrial fibrillation. Heart Rhythm. 2010; 7: 438-444.
114. Manning WJ, Silverman DI, Katz SE, et al. Impaired left atrial mechanical function after cardioversion: relation to the duration of atrial fibrillation. J Am Coll Cardiol, 1994; 23: 1535-1540. (Pubitemid 24182115)
115. Manning WJ, Silverman DI, Katz SE, et al. Temporal dependence of the return of atrial mechanical function on the mode of cardioversion of atrial fibrillation to sinus rhythm. Am J Cardiol, 1995; 75: 624-626.
116. Fatkin D, Kuchar DL, Thorburn CW, et al. Transesophageal echocardiography before and during direct current cardioversion of atrial fibrillation: evidence for "atrial stunning" as a mechanism of thromboembolic complications. J Am Coll Cardiol, 1994; 23:307-316. (Pubitemid 24049357)
117. Cakulev I, Efimov IR, Waldo AL: Cardioversion. Past, present, and future. Circulation, 2009; 120: 1623-1632.
118. Grimm RA, Leung D Y, Black I W, et al. Left atrial appendage "stunning" after spontaneous conversion of atrial fibrillation demonstrated by trans-esophageal Doppler echocardiography. Am Heart J, 1995; 130:174-176.
119. Daoud EG, Marcovitz P, Knight B P, et al. Short-term effect of atrial fibrillation on atrial contractile function in humans. Circulation, 1999; 99: 3024-3027. (Pubitemid 29270432)
120. Leistad E, Aksnes G, Verburg E, et al. Atrial contractile dysfunction after short-term atrial fibrillation is reduced by verapamil but increased by BAY K8644. Circulation, 1996; 93: 1747-1754. (Pubitemid 26131353)
121. Nattel S. New ideas about atrial fibrillation 50 years on. Nature., 2002; 415:219-226. (Pubitemid 34059528)
122. Van Gelder, I. C, Groenveld, H. F., Crijns, H. J., Tuininga, Y. S., Tijssen, J. G., Alings, A. M., et al Lenient versus strict rate control in patients with atrial fibrillation. N Engl J Med, 2010; 362, 1363-1373.
123. Jurkiewicz NK, Sanguinetti MC. Rate-dependent prolongation of cardiac action potentials by a methanesulfonanilide class III antiarrhythmic agent. Specific block of rapidly activating delayed rectifier K+ current by dofetilide. Circ Res, 1993;71:75-83
124. + current and experimental atrial fibrillation in guinea-pig hearts. J Pharmacol Sci, 2007; 105, 229-239. (Pubitemid 350145942)
125. Takács J, Iost N, Lengyel C, Virág L, Nesic NT, Varró A, Papp. J Gy. Multiple amiodarone like cellular electrophysiological effects of azimilide in canine cardiac preparations. Eur. J. Pharmacol., 470, 163-170, 2003. (Pubitemid 36694472)
126. Pritchett EL, Page RL, Connolly SJ, Marcello SR, Schnell DJ, Wilkinson WE. Antiarrhythmic effects of azimilide in atrial fibrillation: efficacy and dose-response. J Am Coll Cardiol, 2000; 36:794-802.
127. Page RL, Connolly SJ, Wilkinson WE, Marcello SR, Schnell DJ, Pritchett EL, Azimilide supraventricular arrhythmia program (ASAP). Investigators. Antiarrhythmic effects of azimilide in paroxysmal supraventricular tachycardia: efficacy and dose-response. Am Heart J. 2002; 143:643-649. (Pubitemid 34454697)
128. Levy, S. (2006). Do We Need Pharmacological Therapy for Atrial Fibrillation in the Ablation Era? J Interv Card Electrophysiol, 17, 189-194. (Pubitemid 46626269)
129. Pratt, C. M., Singh, S. N, Al Khalidi, H. R., Brum, J. M., Holroyde, M. J., Marcello, S. R., et al The efficacy of azimilide in the treatment of atrial fibrillation in the presence of left ventricular systolic dysfunction: results from the azimilide postinfarct survival evaluation (ALIVE) trial. J Am Coll Cardiol, 2004; 43:1211-1216. (Pubitemid 38452599)
130. Pratt CM, Al-Khalidi HR, Brum JM, Holroyde MJ, Schwartz PJ, Marcello SR et al Azimilide trials investigators. Cumulative experience of azimilide-associated torsades de pointes ventricular tachycardia in the 19 clinical studies comprising the azimilide database. J Am Coll Cardiol, 2006; 48:471-477. (Pubitemid 44109955)
131. Thomas GP, Gerlach U, Antzelevitch C. HMR 1556, a potent and selective blocker of slowly activating delayed rectifier potassium current. J Cardiovasc Pharmacol, 2003; 41:140-147. (Pubitemid 36015066)
132. Nakashima H, Gerlach U, Schmidt D, Nattel S. in vivo electrophysiological effects of a selective slow delayed-rectifier potassium channel blocker in anesthetized dogs: potential insights into class III actions. Cardiovasc Res, 2004; 61:651-652.
133. Ks) and the repolarization reserve. Ann Noninvasive Electrocardiol, 2007; 12:64-78. (Pubitemid 46184558)
134. Persson F, Carlsson L, Duker G, Jacobson I. Blocking characteristics of hKv1.5 and Kv4.3/hKChIP2.2 after administration of the novel antiarrhythmic compound AZD7009. J Cardiovasc Pharmacol, 2005; 46:7-17. (Pubitemid 40917773)
135. Persson F, Carlsson L, Duker G, Jacobson I. Blocking characteristics of hERG, hNav1.5, and KvLQT1/hminK after administration of the novel antiarrhythmic compound AZD7009. J Cardiovasc Electrophysiol, 2005, 16:329-341. (Pubitemid 40404601)
136. Carlsson L, Chartier D, Nattel S. Characterization of the in vivo and in vitro electrophysiological effects of the novel antiarrhythmic agent AZD7009 in atrial and ventricular tissue of the dog. J Cardiovasc Pharmacol, 2006; 47:123-132. (Pubitemid 44378235)
137. Löfberg L, Jacobson I, Carlsson L. Electrophysiological and antiarrhythmic effects of the novel antiarrhythmic agent AZD7009: a comparison with azimilide and AVE0118 in the acutely dilated right atrium of the rabbit in vitro. Europace, 2006; 8:549-557. (Pubitemid 43985496)
138. Geller JC, Egstrup K, Kulakowski P, Rosenqvist M, Jansson MA, Berggren A, Edvardsson N, Sager P, Crijns HJ. Rapid conversion of persistent atrial fibrillation to sinus rhythm by intravenous AZD7009. J Clin Pharmacol., 2009; 49(3):312-322.
139. Varró A, Takács J, Németh M, Hála O, Virág L, Iost N, et al Electrophysiological effects of dronedarone (SR 33589), a noniodinated amiodarone derivative in the canine heart: comparison with amiodarone. Br J Pharmacol, 2001; 133:625-633.
140. Moro S, Celestino D, Elizari MV, Sicouri S. Acute amiodarone and dronedarone reduce transmural dispersion of repolarisation and abolished early after depolarisation (EADs) in the canine ventricle. PACE, 1999; 22: 786.
141. Sun W, Sarma JSM, Singh BN. Electrophysiological effects of dronedarone (SR 33589), a noniodinated benzofuran derivative, in the rabbit heart. Comparison with amiodarone. Circulation, 1999; 100:2276-2281.
142. Singh BN, Connolly S.J, Crijns HJ, Roy D, Kowey PR, Capucci A et al EURIDIS ADONIS Investigators. Dronedarone for maintenance of sinus rhythm in atrial fibrillation or flutter. N Engl J Med, 2007;357:987-999. (Pubitemid 47367078)
143. Wegener FT, Ehrlich JR, Hohnloser SH. Dronedarone: an emerging agent with rhythm- and rate-controlling effects. J Cardiovasc Electrophysiol, 2006;17:S17-20. (Pubitemid 44166635)
144. Hohnloser SH, Crijns HJ, van Eickels M, Gaudin C, Page RL, Torp-Pedersen C, Connolly SJ; ATHENA Investigators. Effect of dronedarone on cardiovascular events in atrial fibrillation. N Engl J Med. 2009 Feb 12;360(7):668-78.
145. Erratum in: N Engl J Med, 2009; 360:2487.
146. Burashnikov A, Belardinelli L, Antzelevitch C. Acute dronedarone is
147. Patel, C, Yan, G. X., & Kowey, P. R. Dronedarone. Circulation, 2009;120, 636-644.
148. Dagres N, Sommer P, Anastasiou-Nana M, Hindricks G. Treating arrhythmias: an expert opinion. Expert Opin Pharmacother. 2011, 12:1359-1367.
149. + current in rat ventricular myocytes. Am J Physiol, 1989; 257, H1746-H1749.
150. Wettwer, E., Himmel, H. M., Amos, G. J., Li, Q., Metzger, F., & Ravens, U. Mechanism of block by tedisamil of transient outward current in human ventricular subepicardial myocytes. Br J Pharmacol, 1998; 125, 659-666. (Pubitemid 28482604)
151. Jost N, Virág L, Hála O, Varró A, Thormählen D, Papp JG. Effect of the antifibrillatory compound tedisamil (KC-8857) on transmembrane currents in mammalian ventricular myocytes. Curr Med Chem, 2004; 11:3219-3228. (Pubitemid 39534747)
152. Sridhar A, da Cunha DN, Lacombe VA, Zhou Q, Fox JJ, Hamlin RL, Carnes CA. The plateau outward current in canine ventricle, sensitive to 4-aminopyridine, is a constitutive contributor to ventricular repolarization. Br J Pharmacol, 2007; 152:870-879. (Pubitemid 350100487)
153. h blocker AVE0118 on ion channels in human chronic atrial fibrillation. Br J Pharmacol. 2008; 154:1619-1630.
154. Decher, N, Kumar, P., Gonzalez, T., Pirard, B., & Sanguinetti, M. C. Binding site of a novel Kv1.5 blocker: a "Foot in the Door" against atrial fibrillation. Mol Pharmacol, 2006; 70, 1204-1211. (Pubitemid 44435971)
155. Gogelein, H., Brendel, J., Steinmeyer, K., Strubing, C, Picard, N, Rampe, D., et al Effects of the atrial antiarrhythmic drug AVE0118 on cardiac ion channels. Naunyn Schmiedebergs Arch Pharmacol, 2004; 370, 183-192. (Pubitemid 39361854)
156. Blaauw Y, Gogelein H, Tieleman RG, van Hunnik A, Schotten U, Allessie MA. 'Early' class III drugs for the treatment of atrial fibrillation: efficacy and atrial selectivity of AVE0118 in remodeled atria of the goat. Circulation, 2004; 110:1717-24. (Pubitemid 39299211)
157. Kur) over other cardiac ion channels. Circulation; 118: S-342.
158. Rivard L, Shiroshita-Takeshita A, Maltais C, Ford J, Pinnock R, Madge D et al Electrophysiological and atrial antiarrhythmic effects of a novel IKur/Kv1.5 blocker in dogs. (abstract). Heart Rhythm, 2005;2:S180.
159. Shiroshita-Takeshita A, Ford J, Madge D, Pinnock R, Nattel S. Electrophysiological and atrial antiarrhythmic effects of a novel IKur/Kv1.5 blocker in dogs with atrial tachycardia remodeling. (Abstract). Heart Rhythm 2006;3:S183.
160. + channels and ultrarapidly activating delayed rectifier potassium current. J Pharmacol Exp Ther, 2006; 317:1054-1063. (Pubitemid 43764108)
161. Fedida, D., Orth, P. M., Chen, J. Y, Lin, S., Plouvier, B., Jung, G., et al The mechanism of antiarrhythmic action of RSD1235. J Cardiovasc Electrophysiol. 2005; 16, 1227-1238.
162. Kozlowski D, Budrejko S, Lip GY, Mikhailidis DP, Rysz J, Raczak G, Banach M. Vernakalant hydrochloride for the treatment of atrial fibrillation. Expert Opin Investig Drugs., 2009; 18:1929-1937.
163. Camm AJ, Capucci A, Hohnloser SH, Torp-Pedersen C, Van Gelder IC, Mangal B, Beatch G; AVRO Investigators. A randomized active-controlled study comparing the efficacy and safety of vernakalant to amiodarone in recent-onset atrial fibrillation J Am Coll Cardiol, 2011; 57:313-321.
164. Hondeghem, L. M., & Katzung, B. G. Antiarrhythmic agents: the modulated receptor mechanism of action of sodium and calcium channel-blocking drugs. Annu Rev Pharmacol Toxicol, 1984; 24, 387-423. (Pubitemid 14129541)
165. Antzelevitch, C. & Burashnikov, A. Atrial selective sodium channel block as a novel strategy for the management of atrial fibrillation. J. Electrocardiol, 2009; 42, 543-548.
166. Burashnikov A, Antzelevitch C. New developments in atrial antiarrhythmic drug therapy. Nat. Rev. Cardiol, 2010; 7, 139-148.
167. Burashnikov, A., Di Diego, J. M., Zygmunt, A. C, Belardinelli, L. & Antzelevitch, C. Atrium-selective sodium channel block as a strategy for suppression of atrial fibrillation: differences in sodium channel inactivation between atria and ventricles and the role of ranolazine. Circulation. 2006; 116, 1449-1457. (Pubitemid 47480635)
168. +) currents in atrial fibrillation effects of ranolazine on arrhythmias and contractility in human atrial myocardium. J Am Coll Cardiol, 2010, 55: 2330-2342.
169. Toussaint D, Christ T, Wettwer E, Ravens U. Late sodium current as a promising antiarrhythmic drug target for treatment of atrial fibrillation? (DFG-2011 Meeting abstract). Naunyn-Schmiedeberg's Arch Pharmacol, 2011, 383 (Suppl 1): 61.
170. Antzelevitch C, Belardinelli L, Zygmunt AC, Burashnikov A, Di Diego JM, Fish JM et al Electrophysiological effects of ranolazine, a novel antianginal agent with antiarrhythmic properties. Circulation, 2004; 110: 904-107.
171. Scirica BM, Morrow DA, Hod H, Murphy SA, Belardinelli L, Hedgepeth CM et al Effect of ranolazine, an antianginal agent with novel electrophysiological properties, on the incidence of arrhythmias in patients with non ST- segment elevation acute coronary syndrome: results from the metabolic efficiency with ranolazine for less ischemia in non ST-elevation acute coronary syndrome thrombolysis in myocardial infarction 36 (MERLIN-TIMI 36) randomized controlled trial. Circulation, 2007; 116:1647-1652. (Pubitemid 47537839)
172. Nattel, S., Khairy, P., Roy, D., Thibault, B., Guerra, P., Talajic, M., et al New approaches to atrial fibrillation management: a critical review of a rapidly evolving field. Drugs, 2002; 62, 2377-2397. (Pubitemid 35316387)
173. Bettoni, M. & Zimmermann, M. Autonomic tone variations before the onset of paroxysmal atrial fibrillation. Circulation, 2002; 105, 2753-2759. (Pubitemid 34615147)
174. Pappone, C. et al Pulmonary vein denervation enhances long-term benefit after circumferential ablation for paroxysmal atrial fibrillation. Circulation, 2004; 109, 327-334. (Pubitemid 38133899)
175. Kovoor, P., Wickman, K., Maguire, C. T., Pu, W., Gehrmann, J., Berul, C. I, et al Evaluation of the role of I(KACh) in atrial fibrillation using a mouse knockout model. J Am Coll Cardiol, 2001; 37, 2136-2143. (Pubitemid 32548010)
176. Matsuda, T., Ito, M., Ishimaru, S., Tsuruoka, N., Saito, T., Iida-Tanaka, N., et al Blockade by NIP-142, an antiarrhythmic agent, of carbachol-induced atrial action potential shortening and GIRK1/4 Channel. J Pharmacol Sci, 2006; 101, 303-310. (Pubitemid 44285177)
177. ACh channels in patients with chronic atrial fibrillation. Cardiovasc Res, 2007; 74: 426-437. (Pubitemid 46693702)
178. ACh single channel activity with atrial tachycardia remodeling in canine atrial cardiomyocytes. Cardiovasc Res, 2008; 77: 35-43. (Pubitemid 351195163)
179. Kohajda Z, Kristóf A, Kovács PP, Virag L, Varro A, Jost N. The properties of the transient outward and ultra-rapid delayed rectifier potassium currents in canine atrial myocytes (FCVB 2010 Meeting-2010). Cardiovasc Res, 2010; 87, S51.
180. Jost N., Kohajda Zs., Kovács P.P., Kristóf A., Virág L., Baczkó I, Varró A. Properties of the transient outward, ultra-rapid delayed rectifier and acetylcholine sensitive potassium currents in isolated atrial myocytes from dogs sinus rhythm and tachypaced model of chronic atrial fibrillation (Alpe-Adria Cardiology Congress, 2010). J. Kardiol, 2010; 19, SupplA, 36.
181. 2+ current in canine ventricular cardiomyocytes. Naunyn Schmiedebergs Arch Pharmacol, 2005; 372:63-70. (Pubitemid 41414046)
182. Miyata A, Zipes DP, Hall S, Rubart M. KB-R7943 prevents acute, atrial fibrillation-induced shortening of atrial refractoriness in anesthetized dogs. Circulation, 2002 106:1410-1419. (Pubitemid 35013047)
183. 2+ transient and contractility in canine ventricular cardiomyocytes. Cardiovasc Res., 2008; 78(3)476-484. (Pubitemid 351769762)
184. Kovacs PP, Simon J, Christ T, Werrwer E, Varró A, Ravens U. NCX current is increased in human chronic atrial fibrillation: a possible explanation for contractile dysfunction? (FCVB 2010 Meeting-2010). Cardiovasc Res, 2010; 87, S50.
185. Dhein S, Hagen A, Jozwiak J, Dietze A, Garbade J, Barten M, Kostelka M, Mohr FW. Improving cardiac gap junction communication as a new antiarrhythmic mechanism: the action of antiarrhythmic peptides. Naunyn Schmiedebergs Arch Pharmacol, 2010; 381:221-234.
186. Haugan K, Olsen KB, Hartvig L, et al The antiarrhythmic peptide analog ZP123 prevents atrial conduction slowing during metabolic stress. J Cardiovasc Electrophysiol, 2005; 16: 537-545. (Pubitemid 40632487)
187. Guerra JM, Everett TH 4th, Lee KW, Wilson E, Olgin JE. Effects of the gap junction modifier rotigaptide (ZP123) on atrial conduction and vulnerability to atrial fibrillation. Circulation, 2006; 114:110-8. (Pubitemid 44420742)
188. Laurent G, Leong-Poi H, Mangat I, et al Effects of chronic gap junction conduction-enhancing antiarrhythmic peptide GAP-134 administration on experimental atrial fibrillation in dogs. Circ Arrhythm Electrophysiol, 2009; 2:171-178.
189. Putzke, C, Wemhoner, K., Sachse, F. B., Rinne, S., Schlichthorl, G., Li, X. T., et al The acid-sensitive potassium channel TASK-1 in rat cardiac muscle. Cardiovasc Res, 2007; 75, 59-68. (Pubitemid 46873507)
190. Van Wagoner, D. R., Voigt, N., Bunnell, B., Barnard, J., Schotten, U., Nattel, S., et al Transient receptor potential canonical (TRPC) channel subunit remodeling in clinical and experimental AF. Heart Rhythm Abstract, 2009; PO06-PO77.
191. Bode, F, Sachs, F., & Franz, M. R. Tarantula peptide inhibits atrial fibrillation. Nature, 2001; 409, 35-36. (Pubitemid 32098613)
192. Goette A, Bukowska A, Lendeckel U. Non-ion channel blockers as antiarrhythmic drugs (reversal of structural remodeling). Curr Opin Pharmacol, 2007; 7:219-224. (Pubitemid 46404738)
193. Savelieva I, Camm J. Statins and polyunsaturated fatty acids for treatment of atrial fibrillation. Nat Clin Pract Cardiovasc Med, 2008; 5:30-41.
194. Ducharme A, Swedberg K, Pfeffer MA, et al Prevention of atrial fibrillation in patients with symptomatic chronic heart failure by candesartan in the can-desartan in heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) program. Am Heart J, 2006;152:86-92.
195. Salehian O, Healey J, Stambler B, et al Impact of ramipril on the incidence of atrial fibrillation: Results of the Heart Outcomes Prevention Evaluation study. Am Heart J, 2007; 154:448-453 (Pubitemid 47271928)
196. Jang JK, Park JS, Kim YH, et al Effects of the therapy with statins, angio-tensin-converting enzyme inhibitors, and angiotensin II receptor blocker on the outcome after catheter ablation of atrial fibrillation (abstract). Heart Rhythm, 2008; 5:S324
197. Berkowitsch A, Neumann T, Kuniss M, Janin S, Wojcik M, Zaltsberg S, Mitrovic V, Pitschner HF Therapy with Renin-Angiotensin system blockers after pulmonary vein isolation in patients with atrial fibrillation: who is a responder? Pacing Clin Electrophysiol, 2010; 33:1101-1011.
198. Lin CS, Pan CH. Regulatory mechanisms of atrial fibrotic remodeling in atrial fibrillation. Cell Mol Life Sci, 2008; 65:1489-1508.